Search & Analyze

Ipca Laboratories Ltd.

HealthcarePharmaceuticals & Drugs

www.ipca.com BSE: 524494NSE: IPCALAB

₹1,961.05BSE0.74%

07 Sep, 4:01 PM

₹1,961.05

₹49.70K Cr

37.95

5.86

15.88%

₹1,978.00

₹1,944.95

₹1,999.00

₹1,252.95

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
Ipca Laboratories Ltd. IPCALAB	1,961.05	37.95	49,704.46	0.31	424.27	82.18%	2,788.10	20.76%	19.41

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,033.03	2,092.63	2,354.90	2,245.37	2,246.69	2,308.85	2,556.50	2,392.50	2,388.48	2,788.10
Expenses	1,711.13	1,699.91	1,913.42	1,782.29	1,817.83	1,892.43	2,011.58	1,859.15	1,904.61	2,118.59
	321.90	392.72	441.48	463.08	428.86	416.42	544.92	533.35	483.87	669.51
	15.83%	18.77%	18.75%	20.62%	19.09%	18.04%	21.32%	22.29%	20.26%	24.01%
	-117.80	20.61	26.26	20.11	-179.23	32.66	-30.40	37.84	47.92	25.26
Interest	29.37	24.05	22.56	16.81	21.51	18.51	19.61	17.62	20.20	11.88
	98.13	98.89	100.35	98.46	100.12	100.06	103.33	107.59	107.14	110.81
	75.02	290.55	345.14	366.95	126.21	328.98	388.61	445.60	401.74	573.54
	98.23%	31.46%	28.80%	24.69%	49.30%	29.21%	27.81%	18.39%	23.66%	26.03%
	59.59	192.24	229.48	248.14	67.82	233.21	282.57	326.27	299.07	401.89
	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	5,829.79	6,244.32	7,705.04	8,939.59	9,646.33
Less: Excise Duty	33.05	40.06	42.61	42.78	47.31
	5,796.74	6,204.26	7,662.43	8,896.81	9,599.02
EXPENDITURE :
Increase/Decrease in Stock	-129.65	100.67	-130.64	-46.05	-53.91
Raw Material Consumed	1,920.43	1,978.83	2,382.37	2,490.66	2,540.07
Power & Fuel Cost	242.12	283.74	333.97	351.23	365.09
Employee Cost	1,177.39	1,287.64	1,708.43	1,983.99	2,160.20
Other Manufacturing Expenses	610.03	655.66	892.99	966.04	1,055.48
General and Administration Expenses	261.34	296.10	345.05	387.39	425.70
Selling and Distribution Expenses	402.81	595.47	745.87	917.41	973.11
Miscellaneous Expenses	54.65	102.88	120.34	175.61	178.81
	4,539.12	5,300.99	6,398.38	7,226.28	7,644.55
Operating Profit (Excl OI)	1,257.62	903.27	1,264.05	1,670.53	1,954.47
	121.72	151.77	184.36	151.32	201.69
	1,379.34	1,055.04	1,448.41	1,821.85	2,156.16
Interest	11.20	48.19	140.75	87.84	79.09
PBDT	1,368.14	1,006.85	1,307.66	1,734.01	2,077.07
	232.42	261.56	357.24	397.82	418.12
Profit Before Taxation & Exceptional Items	1,135.72	745.29	950.42	1,336.19	1,658.95
Exceptional Income / Expenses			-107.75	-205.05	-86.43
	1,135.72	745.29	842.67	1,131.14	1,572.52
Provision for Tax	224.77	253.36	313.46	343.61	381.15
	910.95	491.93	529.21	787.53	1,191.37
Extra items				0.00	0.00
Minority Interest	-5.71	-7.67	24.43	-47.56	-42.66
Share of Associate	-21.16	-12.94	-6.29	-2.29	-7.59
Consolidated Net Profit	884.08	471.32	547.35	737.68	1,141.12
Profit Balance B/F	3,247.75	4,036.06	4,404.01	4,899.35	5,531.33
Appropriations	4,131.83	4,507.38	4,951.36	5,637.03	6,672.45
Equity Dividend %	400.00%	400.00%	400.00%	400.00%	600.00%
	34.85	18.58	21.57	29.08	44.98
Adjusted EPS	34.85	18.58	21.57	29.08	44.98

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	25.37	25.37	25.37	25.37	25.37
Share Warrants & Outstandings			1.61	2.70	3.14
Total Reserves	5,439.47	5,816.65	6,305.21	6,920.38	8,035.30
Reserve excluding Revaluation Reserve	5,439.47	5,816.65	6,305.21	6,920.38	8,035.30
	5,464.84	5,842.02	6,332.19	6,948.45	8,063.81
Minority Interest	76.92	73.30	1,394.81	1,439.82	1,460.25
Secured Loans	395.18	651.78	580.41	543.24	109.12
Deferred Tax Assets / Liabilities	162.36	185.59	306.24	278.05	224.32
Other Long Term Liabilities	13.60	17.36	40.92	51.54	87.31
Long Term Provisions	42.73	46.99	86.84	96.31	97.91
Total Non-Current Liabilities	613.87	901.72	1,014.41	969.14	518.66
Trade Payables	557.70	525.06	776.08	846.17	940.29
Other Current Liabilities	420.52	488.15	732.62	725.45	732.07
Short Term Borrowings	367.81	661.82	559.24	495.25	417.49
Short Term Provisions	119.85	130.79	287.70	317.42	217.08
Total Current Liabilities	1,465.88	1,805.82	2,355.64	2,384.29	2,306.93
Total Liabilities	7,621.51	8,622.86	11,097.05	11,743.63	12,349.65
Gross Block	3,749.46	4,353.42	7,020.79	6,994.56	7,721.79
Less: Accumulated Depreciation	1,331.43	1,602.04	2,467.26	2,727.75	3,094.90
Less: Impairment of Assets	15.84
Net Block	2,402.19	2,751.38	4,553.53	4,266.81	4,626.89
Capital Work in Progress	293.85	122.17	323.59	616.17	761.59
Non Current Investments	269.88	302.66	303.61	216.32	210.14
Long Term Investment	269.88	302.66	303.61	216.32	210.14
Long Term Loans & Advances	169.63	229.61	315.59	317.29	336.37
Other Non Current Assets	16.21	9.51	42.53	52.90	26.30
Total Non-Current Assets	3,164.34	3,433.59	5,558.15	5,475.09	5,972.79
Currents Investments	719.31	323.32	558.40	763.39	633.42
Inventories	1,857.97	1,743.37	2,471.31	2,560.42	2,731.00
Sundry Debtors	910.78	989.02	1,686.51	1,884.14	2,014.26
Cash and Bank	640.66	1,853.24	296.84	344.23	564.59
Other Current Assets	116.19	124.70	325.01	120.25	160.77
Short Term Loans and Advances	201.80	155.62	197.48	294.61	269.57
Total Current Assets	4,446.71	5,189.27	5,535.55	5,967.04	6,373.61
Net Current Assets (Including Current Investments)	2,980.83	3,383.45	3,179.91	3,582.75	4,066.68
Total Assets	7,621.51	8,622.86	11,097.05	11,743.63	12,349.65
Contingent Liabilities	69.67	93.44	119.12	234.86	249.19
Total Debt	791.24	1,457.53	1,387.50	1,301.70	703.94
	215.41	230.27	249.53	273.78	317.72
Adjusted Book Value	215.41	230.27	249.53	273.78	317.72

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	1,135.72	745.29	842.67	1,131.14	1,572.52
Adjustment	195.11	235.18	489.87	727.89	277.35
Changes In working Capital	-272.72	48.99	-91.59	-176.46	-293.95
Cash Flow after changes in Working Capital	1,058.11	1,029.46	1,240.95	1,682.57	1,555.92
Cash Flow from Operating Activities	856.07	805.81	944.65	1,321.32	1,141.97
Cash Flow from Investing Activities	-855.05	-725.00	-1,291.79	-869.50	-246.77
Cash Flow from Financing Activitie	426.78	507.24	-552.55	-282.98	-753.53
Net Cash Inflow / Outflow	427.80	588.05	-899.69	168.84	141.67
Opening Cash & Cash Equivalents	559.01	990.93	1,578.98	755.79	924.63
Cash & Cash Equivalent on Amalgamation / Take over / Merger	4.12		76.50
Closing Cash & Cash Equivalent	990.93	1,578.98	755.79	924.63	1,066.30

Ratios

Valuation

37.95

5.86

20.78

4.91

51.63

334.38

Profitability

15.88

19.41

9.89

20.26

12.35

Leverage & Liquidity

0.09

2.76

20.88

Returns

0.31

0.80

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	46.30	46.30	44.72	44.72	44.72	44.72	44.72	44.72	44.72
	44.63	45.05	46.74	46.82	46.87	47.20	47.95	48.08	48.10
	9.07	8.65	8.53	8.46	8.41	8.08	7.33	7.20	7.18
	53.70	53.70	55.28	55.28	55.28	55.28	55.28	55.28	55.28
No. of Shareholders	84,753	82,975	90,189	88,306	85,582	82,870	77,673	82,184	82,060

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-28	Board Meeting	Quarterly Results
2026-07-13	AGM
2026-05-29	Ex Dividend	Rs.6.0000 per share(600%)Dividend	2026-08-07	2026-08-07

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Ipca Laboratories Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Harish P Kamath

Corporate Counsel & Company Secretary, Compliance Officer

—

Premchand Godha

Chairman

₹14.97 Cr

Mar '26

Ajit Kumar Jain

Managing Director & CFO

₹10.60 Cr

Mar '26

Pranay Godha

Managing Director & CEO

₹9.95 Cr

Mar '26

Prashant Godha

Executive Director

₹7.19 Cr

Mar '26

Kamal Kishore Seth

Non Executive Independent Director

₹14.50 L

Mar '26

Narendra Mairpady

Non Executive Independent Director

₹11.50 L

Mar '26

Swati Patankar

Non Executive Independent Director

₹9.50 L

Mar '26

Vivek Shiralkar

Non Executive Independent Director

₹12.50 L

Mar '26

IPCALAB Latest News

News

8 of 8 articles

EQUITY17 Aug 2026 · 16:29

Ipca Laboratories informs about analyst meet outcome

EQUITY28 Jul 2026 · 10:06

Ipca Laboratories informs about board meeting

EQUITY14 Jul 2026 · 13:13

Ipca Laboratories submits BRSR

EQUITY14 Jul 2026 · 11:22

Ipca Laboratories informs about annual report

EQUITY22 Jun 2026 · 11:25

Ipca Laboratories informs about trading window closure

COMPANY15 Jun 2026 · 14:10

Ipca Laboratories inks global licensing agreement with Bhami’s Research Laboratory

The company has been granted access to BRL's proprietary high-concentration subcutaneous biologics delivery platform

EQUITY9 Jun 2026 · 16:39

Ipca Laboratories informs about newspaper publication

EQUITY29 May 2026 · 13:55

Ipca Laboratories reports Profit after tax of Rs 2622.90 Mln, in the March 2026 quarter

IPCALAB

₹1,961.05

-0.74%